论文信息 - Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). - 字舞流文

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Plimack | M. Voss | P. Sharma | B. Rini | M. Ernstoff | J. Infante | J. Knox | C. Kollmannsberger | S. Pal | D. Heng | D. McDermott | H. Hammers | J. Spratlin | J. Kurland | Yun Shen | A. Amin | P. Gagnier | Padmanee Sharma